4//SEC Filing
Busch Andreas 4
Accession 0001209191-19-058158
CIK 0001755237other
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 5:41 PM ET
Size
6.1 KB
Accession
0001209191-19-058158
Insider Transaction Report
Form 4
Busch Andreas
Chief Innovation Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2019-11-22+75,000→ 75,000 totalExercise: $2.01Exp: 2029-11-22→ Common Stock (75,000 underlying)
Footnotes (2)
- [F1]The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021.
- [F2]To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled.
Documents
Issuer
Cyclerion Therapeutics, Inc.
CIK 0001755237
Entity typeother
Related Parties
1- filerCIK 0001775029
Filing Metadata
- Form type
- 4
- Filed
- Nov 25, 7:00 PM ET
- Accepted
- Nov 26, 5:41 PM ET
- Size
- 6.1 KB